When a former FDA Official testified that Eli Lilly lied about Drug Side-Effects…

NaturalNews, September 06, 2008

Former FDA Official Testifies that Eli Lilly Lied about Drug Side Effects
Eli Lilly made $27.7 Billion in Profits between 2003-2012 – sources HuffPolitics Blog

Gueriguian testified that Eli Lilly knew as early as 1998 that Zyprexa increased the risk of developing diabetes, but did not issue warnings about those effects until 2007
Simply put, it’s putting profit over the concern of the consumer‘, Gueriguian said “.

Read Former FDA Official Testifies that Eli Lilly Lied about Drug Side Effects by David Gutierrez, September 06, 2008

All our posts tagged Eli Lilly – Big PharmaDrugs

All Trials Registered, All Results Reported, why the Campaign Matters

Read more information and see how you can help

All Trials Registered, All Results Reported, why the #AllTrials Campaign Matters
Join and sign the #AllTrials petition for all trials registered and all results reported

Around half of all clinical trials have not been published; some trials have not even been registered. If action is not taken urgently, information on what was done and what was found in trials could be lost forever, leading to bad treatment decisions, missed opportunities for good medicine, and trials being repeated unnecessarily.

Environment and sustainable Health, Children with Cancer, Pregnancy and Drugs: our Responsability

Our children will accuse us

In 2008, in a little village in France, the mayor decided to take action and to move to bio food for their school… so that tomorrow, their children will not accuse them…

Historical Review of the DES Tragedy, glaring Example of what NOT to do in Medicine…

The Diethylstilbestrol tragedy thorough historical review

Problems in Research: Regulations—The Diethylstilbestrol Tragedy
The diethylstilbestrol tragedy: a failure of oversight or poor science?

For a thorough historical review of the DES tragedy take a moment and read this lengthy call for tighter FDA regulation of the drug industry. The DES story makes a compelling case!

DES Action USA commented: ” Thank you for this call for stronger government regulation of pharmaceuticals. The DES tragedy makes a compelling case and you tell the story well. Adding insult to injury, it isn’t correct to say that in 1971 the FDA banned DES for most uses. Sadly, DES was only ‘contraindicated’ so it was well into the 1970s before doctors stopped prescribing DES to pregnant women! Either they didn’t get the word, or they felt they knew better than government regulators. Many doctors now dismiss DES exposure as ‘not a problem anymore’ but millions of us were exposed before birth and live with the health problems it caused. We fervently wish similar tragedies wouldn’t happen again – but sadly, the DES lessons learned are being ignored.

Read Problems in Research: Regulations—The Diethylstilbestrol Tragedymedicalbag, April 12, 2013.

More DES DiEthylStilbestrol Resources

Suspension of FDA Approval urged for new Morning Sickness Drug Diclegis

Another preventable future health tragedy?

#Diclegis is #FDA approved to replace #Bendectin as new Morning Sickness DrugJill Escher, from Prenatal Exposures Never Die, the blog about epigenetics, autism, and the multigenerational tragedy of prenatal pharmaceutical use, wrote to the FDA on April 11. 2013.

I am writing to urgently request that the FDA take immediate steps to suspend approval for the prenatal drug Diclegis pending appropriate safety testing for impacts to fetal germ cells, the precursor cells to the baby’s egg or sperm. In addition, I urge the FDA to take immediate steps to issue warnings regarding potential germline impact of all prenatally administered drugs… ”

Read Suspension of Approval Urged for New Morning Sickness Drug, Diclegis, Pending Assessment of Fetal Germline Impacts, April 11. 2013.

Related post: Diclegis FDA approved to replace Bendectin as new Morning Sickness Drug: future Health Tragedy?.

Diclegis FDA approved to replace Bendectin as new Morning Sickness Drug

Another preventable future health tragedy?

#Diclegis is #FDA approved to replace #Bendectin as new Morning Sickness DrugA new pregnancy drug, the Diclegis® pill manufactured by  Duchesnay Inc. Canada, will enter pharmacies this June 2013.  This week (see tweet), in its news release, the FDA stated: ” The U.S. Food and Drug Administration today approved Diclegis (doxylamine succinate and pyridoxine hydrochloride) to treat pregnant women experiencing nausea and vomiting “.

The “Morning Sickness Drug“, was called Bendectin between 1978 and 1983, and had over 300 lawsuits filed against the Merrell Dow pharmaceutical company, claiming damages for babies with deformities born to mothers who took the drug. The wide range of birth defects attributed to it were: limb and other musculoskeletal deformities; facial and brain damage; defects of the respiratory, gastrointestinal, cardiovascular and genital-urinary systems; blood disorders and cancer.

With many thanks to Judith Kavanaugh for warning me about this unbelievable but true news !!!

More information

The Push to Prescribe

Women and Canadian Drug Policy, by Anne Rochon Ford and Diane Saibil

The Push to prescribe: Women and Canadian Drug Policy, by Anne Rochon Ford and Diane Saibil on Flickr
The Push to prescribe: Women and Canadian Drug Policy, by Anne Rochon Ford and Diane Saibil.

In recent years, heated debate has surrounded the pharmaceutical industry and how it has gained unprecedented control over the evaluation, regulation, and promotion of its own products. As a result, drugs are produced, regulated, marketed, and used in ways that infiltrate many aspects of everyday life. The nature and extent of this infiltration, and how this has special meaning for women, are at the core of The Push to Prescribe.

The book delves into the world of prescription drugs in Canada, and considers the impact on the health of women. From the inadequate testing of many drugs on women in clinical trials, to the sometimes questionable portrayal of women in illegal prescription drug advertising, Canadian drug policy has not always paid attention to how women and men are affected differently.

This is an essential resource for a variety of courses in Health Sciences, Medicine, Nursing, Pharmacology, Public Policy, Public Health, Health Policy, Women’s Studies, Women’s Health, as well as many Social Science courses in areas like Sociology and Political Science. It will also be of interest to a general audience, health professional organizations, government health associations, and consumer and women’s groups.

SPECIAL FEATURES

  • presents an approach that combines compelling evidence with social, political, and gender-based analyses
  • discusses the complexity surrounding women and pharmaceuticals and uses the best evidence to argue for changes that better reflect women’s needs in public health policy and that ensure those who are best suited to make these determinations are included in policy-making

RELATED LINKS

Anti-Depressants in Pregnancy: is there Evidence of Benefit?

Do antidepressant medications work the way they are supposed to?

Watch the webinar discussion  about women and Canadian drug policyAntidepressants are increasingly being used to treat depression in pregnancy in Canada despite their lack of approval for this use by Health Canada or the US FDA. Recent scientific and public attention has focused on an increased risk for infants, and this has led to conflicting advice about the use of SSRI/SNRI antidepressants (such as Prozac, Paxil, Effexor, or other related drugs) during pregnancy. Some suggest avoiding all exposures, while others recommend use in order to avoid harm to mothers and infants from untreated depression.

In 2009, Dr. Barbara Mintzes presented what she and colleagues found in a systematic evaluation of all available studies comparing women with depression who did or did not take antidepressants during pregnancy. Their goal was to find an answer to the controversial and urgent clinical question: do pregnant women benefit from taking antidepressants?

Watch the webinar discussion  about women and Canadian drug policy.

You watched the webinar? Please share your thoughts!

Why Researchers MUST publish ALL Results of Clinical Trials

Make all medical research results public

Make all research results publicA new campaign All trials registered, all results reported  – supported by the Medical Research Council  (publicly funded organisation in the UK dedicated to improving human health) – calls for the results of all clinical trials to be made public.
Sir Iain Chalmers, Coordinator of the James Lind Initiative, has strong words on researchers who hide trial results and ends his post by saying: “ If action is not taken urgently by research funders and regulators, information on what was done and what was found in trials could be lost forever, leading to bad treatment decisions, unnecessary repetition of trials, and missed opportunities for good medical practice. ”

Read Make all research results public, insight, 4 April 2013.
#AllTrials website and donation site.

Watch the Seattle Book Discussion about Bad Pharma

How Drug Companies Mislead Doctors and Harm Patients

Watch the Seattle Book Discussion about Bad Pharma, an 86 min Video with @BenGoldacreLast February 18th, 2013, at Town Hall Seattle, Dr. Ben Goldacre talked about his book, Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients, in which he discusses the influence of the pharmaceutical industry on the global healthcare system and argues that pharmaceutical companies hide negative studies and use questionable testing and intensive lobbying to get what they want, regardless of whether the drugs they produce are good for patients. Watch the video  (1 hour, 26 minutes) .

More about Ben Goldacre

DES Videos in English – Diethylstilboestrol YT video channel.